GlassScriptPhysician profile
Michael A Mecley
NPI 1609828920
$13,133.43
in general payments reported to CMS, 2019-2025
36 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,317 · 2020: $1,681 · 2021: $2,443 · 2022: $1,595 · 2023: $1,520 · 2024: $2,193 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,096.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,895.43 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,712.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,550.17 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $987.27 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $838.00 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $826.77 | 2019-2025 | Farxiga |
| Alnylam Pharmaceuticals INC. | $714.78 | 2020-2025 | Onpattro, Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.33 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $507.28 | 2021-2025 | Verquvo, Capvaxive |
| Amarin Pharma, INC. | $417.11 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $341.91 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $269.43 | 2019-2025 | Watchman Access System, Watchdog, Watchman Flx |
| Novo Nordisk INC | $250.43 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $246.71 | 2021-2025 | |
| Heartflow, INC. | $221.25 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $220.79 | 2019-2022 | |
| Scpharmaceuticals INC. | $215.95 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $210.01 | 2019-2021 | |
| Esperion Therapeutics, INC. | $199.02 | 2020-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $150.42 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Irhythm Technologies, INC. | $121.64 | 2022-2024 | Zio Monitor, Zio Xt Patch |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.32 | 2020-2025 | Lifevest |
| Bardy Diagnostics, INC. | $110.00 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $94.57 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $87.02 | 2022-2023 | |
| Medicomp INC | $46.21 | 2024-2025 | Telepatch Cardiac Monitor |
| Abiomed | $37.89 | 2024 | Impella |
| Philips North America LLC | $35.34 | 2020 | |
| Ge Healthcare | $28.37 | 2025 | |
| Abbott Laboratories | $27.13 | 2022 | |
| Gilead Sciences, INC. | $23.29 | 2019 | |
| Braemar Manufacturing, LLC | $22.89 | 2019 | |
| Covidien LP | $22.35 | 2019 | |
| Baxter Healthcare | $20.68 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Mannkind Corporation | $18.61 | 2025 | |
| Medtronic Vascular, INC. | $14.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mecley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.